Bermekimab

Bermekimab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetIL1A
Clinical data
Trade namesXilonix
Other namesMABp1
Routes of
administration		intravenous
ATC code
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6464H10024N1736O2000S44
Molar mass145468.09 g·mol−1

Bermekimab[1] (MABp1, trade name Xilonix) is a human monoclonal antibody of IgG1k isotype targeting Interleukin 1 alpha (IL1A).[2] As of March 2017, bermekimab is in phase III clinical trials as an immunotherapy for colorectal cancer[3] and as of September 2018 in phase II clinical trials for the treatment of atopic dermatitis.[4]

Bermekimab is being developed by XBiotech Inc.[5]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Bermekimab, American Medical Association.
  2. ^ Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, et al. (May 2014). "MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study". The Lancet. Oncology. 15 (6): 656–66. doi:10.1016/S1470-2045(14)70155-X. PMID 24746841.
  3. ^ Clinical trial number NCT01767857 for "A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer (XCITE)" at ClinicalTrials.gov
  4. ^ Clinical trial number NCT03496974 for "A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis" at ClinicalTrials.gov
  5. ^ "Xilonix True Human monoclonal antibody by Xbiotech oncology". www.xbiotech.com. XBiotech. Retrieved 3 March 2017.